Post

New research · Ophthalmology
Frontiers in immunology · 2d
Cohort studyFrontiers in immunology · 2026

Ophthalmic involvement in VEXAS syndrome and its influence on mortality: insights from the international AIDA network registry.

Jurgen Sota, Andrea Hinojosa-Azaola, Eduardo Martín-Nares … Claudia Fabiani
Read paper
OphthalmologyCohort study

Eye involvement in VEXAS syndrome independently predicts higher odds of death

Ophthalmic involvement in VEXAS syndrome and its influence on mortality: insights from the international AIDA network registry.

Jurgen Sota … Claudia Fabiani
Frontiers in immunology · 2026
Background

Orbital inflammation is the most common presentation of VEXAS, with any orbital structure potentially affected.

OR 3.72
Results
OR 3.72
eye involvement nearly quadruples the odds of dying
More results

Non-sight-threatening and uncomplicated anterior non-granulomatous uveitis and anterior diffuse scleritis follow in frequency, along with episcleritis.

Treatment of ophthalmic involvement showed full or partial response to glucocorticosteroids alone in 66.7% of cases.

“
Conclusion

Ophthalmic involvement is common in VEXAS syndrome and signals a poorer prognosis in terms of mortality, highlighting the need for close monitoring.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving